ResearcherKyoto Prefectural University of MedicineActive in the last 2 years
Toshiyuki Sakai
Matched on ORCID iD 0000-0002-7865-2258; OpenAlex author ID A5013263645. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 3
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 3
- Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-24-0831↗
- MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells. Co-author DOI 10.21873/anticanres.11001↗
- Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. Last author DOI 10.1371/journal.pone.0125779↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ema Toyokuni · 1 shared paper, 2025 · strength 0.30
- Ryoichi Tanaka · 2 shared papers, 2015–2016 · strength 0.15
- Paper MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and… DOI 10.21873/anticanres.11001↗
- Paper Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulatio… DOI 10.1371/journal.pone.0125779↗
- Yoshihiro Sowa · 1 shared paper, 2016 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.